This page shows the latest naltrexone news and features for those working in and with pharma, biotech and healthcare.
The panel also voted by nine votes to six in favour of approving Pfizer's Troxyca ER (oxycodone/naltrexone) for the sane indication. ... In the case of Troxyca ER, the inclusion of opioid blocker naltrexone is designed to achieve the same end result.
The lawsuit alleges that the generic drugmaker Actavis has infringed patents on Orexigen and Takeda's new weight-loss treatment Contrave (naltrexone and bupropion).
s Contrave (bupropion/naltrexone), Arena/Eisai's Belviq (lorcaserin) and Vivus' Qsymia (phentermine/topiramate), although for patients the monthly cost will fall depending on their insurance cover.
the US of three other drugs; Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion).
new products - Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion) in the last couple of years in the US and other world
The drug is a combination of the antidepressant bupropion and Orexigen's formulation of naltrexone, a drug designed to prevent drug dependence. ... The CHMP has recommended a marketing authorisation for Mysimba (naltrexone/bupropion) for weight
More from news
Approximately 5 fully matching, plus 24 partially matching documents found.
SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...